Cancer Partners UK was acquired by GenesisCare UK on the 8th January 2016
Cancer Partners UK has been identified as one of London Stock Exchange’s 1000 Companies to Inspire Britain. The report is a celebration of the UK’s fastest-growing and most dynamic small and medium sized businesses.
To be included in the list, companies needed to show consistent revenue growth over a minimum of three years, significantly outperforming their industry peers. More detail on the methodology can be found in the report online at www.1000companies.com.
- Cancer Partners UK recognised in second edition of London Stock Exchange’s 1000 Companies to Inspire Britain report 2015.
- Identifies fastest-growing and most dynamic small and medium sized businesses (SMEs) in UK.
- Cancer Partners UK provides predominantly private radiotherapy services through regional partnerships with leading local private hospital groups but also comprehensive standalone, diagnostic and treatment centres for day-case patients.
Cancer Partners UK opened its first private radiotherapy centre in August 2009. Just over 5 years on it has radiotherapy centres in, or in the grounds of, private hospitals in Birmingham, Guildford, Nottingham, Portsmouth and Southampton.
In addition, Cancer Partners UK has a standalone cancer treatment centre in partnership with a local hospital in Elstree offering both radiotherapy and chemotherapy treatment and, most recently, has developed diagnostic and treatment centres in Milton Keynes and Oxford. A new diagnostic and treatment centre is currently being developed in Kings Hill, West Malling, Kent and others are to be opened over the next 5 years.
Cancer Partners UK’s CEO, Steve Bird, said:
“People can be concerned about radiotherapy treatment but it plays a vital role in treating and beating cancer. With the incidence of cancer diagnosis on the rise, partly due to our increasing longevity, our consistent combination of highly targeted intensity modulated radiotherapy (IMRT) and daily image guided radiotherapy (IGRT) means we can treat cancer with pinpoint accuracy leading to less side-effects.
For left-sided breast cancer patients, and some patients with thoracic and abdominal cancers, our company-wide approach to using a deep-inspiration breath-hold technique during treatment sessions further reduces the risk of the radiation beam harming vital organs, such as the heart. With patients living far longer than ever before, our aim is to help them achieve a full life with as few future complications as possible.
“However, Cancer Partners UK is not just about how we treat the patient, we also believe that at a difficult and emotional time we should be providing the best support patients could wish for in the circumstances, not just in the comfort of their treatment surroundings, but in our individual approach to patient care and recognition of their holistic care needs.
It may seem common sense but it’s about having time when it is needed and listening to patients, as much as it is about providing state-of-the-art technology to treat their disease. To be the leading provider in cancer care, offering an exemplary patient experience before, during and beyond treatment, is at the core of the company.
“We are delighted to be recognised as one of the companies that stand out for its contribution to service and business growth in the UK from the five million SME businesses which are the backbone of the UK economy.”
Xavier Rolet, Chief Executive, London Stock Exchange Group said:
“This report is a significant part of London Stock Exchange’s broader campaign to support UK high growth companies in their journeys from Start-up to Stardom and to create an entrepreneurship revolution. I’m delighted that a strong alliance between UK Government, financial market participants, investors, entrepreneurs and companies has been created to support these inspiring businesses.”
A full searchable database of all of the companies along with a downloadable pdf of the publication can be found online at www.1000companies.com.